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Thiourea derivatives were much used in drug discovery and drug-making, such as for an 
anticancer. The formation of drug complexes can increase lipophilicity through chelation 
formation, and the drug action is significantly upward due to the effective permeability to the center. 
In another study, the alteration of the compound becomes the complex with metal will grow in its 
activity so recently we have synthesized the Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl) 
Benzamide)-Iron (III) complex.  The synthesis of Fe (III) metal with the 4-(Tert-Butyl)-N-
(Methylcarbamothioyl) Benzamide in ethanol by reflux at 75oC for 7 hours. Hot Stage Microscopy, 
UV-Visible Spectrophotometry Infrared Spectrophotometry, and Massa Spectrophotometry were 
used to characterize the complex. This study concerns representing, inferring, and predicting 
pharmacokinetics and toxicity and molecular docking complexes. The complex weight was 0.29469 
g. Its purity has been tested using the melting point determination and has obtained its range was 
113o-115oC. The Characteristics of Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl) Benzamide)-
Iron(III) complex have a maximum wavelength of 260 nm and provide absorption of Fe-O 
vibrations at wavenumbers 478.2 cm-1 and 588 cm-1, and the m/z complex of spectrophotometry 
mass was 559.31. The molecular docking process was performed using AutodockTools-1.5.6 
software. It showed that Bis-(4-(Tert-Butyl)-N-(Methylcarbamo-thioyl)Benzamide)-Iron(III) 
complex could interact with ribonucleotide reductase enzyme, and it has better interaction than the 
4-(Tert-Butyl)-N-(Methylcarbamothioyl)Benzamide with the binding affinity energy (ΔG)of  -8.52 
kcal/mole and the constant inhibition (Ki ) of 568.55 nM. 
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The World Health Organization (WHO) defines cancer as a large group of diseases that occur 
because cells grow beyond normal limits. Cancer can spread and infect other parts of the body. The 
disease has many anatomical and molecular subtypes, each of which requires special treatment. 
Based on global data in 2018, cancer is the second largest killer with an estimated 9.6 million 
deaths. (Organization, 2018; RI, 2019).  
Thiourea is described as an organic compound containing carbon, nitrogen, hydrogen, and 
sulfur atoms. Thiourea has a similar structure to urea, but it has an S atom which replaces the O 
atom in the urea structure. In previous studies, drug discovery researches were frequently use urea 
as an anticancer.  (Lan et al., 2018; Ren et al., 2014), anti-tuberculosis (Brown et al., 2011; North 
et al., 2013), antimalarial (Domínguez et al., 2005; Schwartz et al., 2015) and as an analgesic 
(Sartori et al., 1994). Thiourea is considerably used as a discovery of new drugs for anticancer and 
antitumor (Karakuş et al., 2009; Manjula et al., 2009; Pingaew et al., 2018; Yang et al., 2013; Yao 
et al., 2012), antibacterial, antimicrobial, and anti-tuberculosis (Bielenica et al., 2018; Binzet et al., 
2018; Khan et al., 2008; Seth et al., 2004; Upadhayaya et al., 2009; Vega-Pérez et al., 2012) soluble 
epoxide hydrolase inhibitor and also as an antiviral (Burmistrov et al., 2018). 
In the previous study, we have synthesized an in vitro test to cancer cells of the 4-(tert-butyl)-
N-(methylcarbamothioyl) benzamide the IC-50 of 111 g/mL. The 4-(tert-butyl)-N-
(methylcarbamothioyl) benzamide is a compound derived from 1-benzoyl-3-methylthiourea 
(Ruswanto et al., 2018). One of the many advances to drug production is to convert compounds 
into metal complexes, making their absorption and distribution and their pharmacological activities 
better (Lin et al., 2008; Mardianingrum et al., 2019; Ruswanto et al., 2019). 
The findings of anticancer drugs is done by synthesizing a complex between 4- (Tert-Butyl) 
-N-Methylcarbamothioyl) Benzamide with Fe (III) metal. It is a new compound in the thiourea 
derivative. Those were described and characterized using Hot Stage Microscopy (HSM), Infrared 
Spectrophotometry, UV-Vis Spectrophotometry, Mass Spectrophotometry, Molecular Docking, 
ADME Toxicity Prediction. 
  
MATERIALS AND METHOD  
Materials and instruments 
We used graduated cylinder, watch glass, analytical scales, Erlenmeyer Bulb, reflux sets, 
magnetic stirrers, thermometers, filter paper, hot plates, 50 mL and 100 mL beakers, crucible, 30 
mL vials, Hot Stage Microscopy, UV-Vis Spectrophotometer, Genesys 10S, Perkin Elmer 
Spectrum 100 FT-IR Spectrometer, and Mass Spectrophotometry (MS). The laptop we used having 
hardware specifications with AMD Ryzen 3 2200U specifications with Radeon Vega Mobile Gfx 
(4 CPUs), 2.5GHz 4GB 64-bit RAM. And its software were ChemDraw Ultra 12.0, MarvinSketch 
5.2, AutodockTools-1.5.6, Discovery Molecular Viewer 16.1, Molegro Molecular Viewer 2.5, and 
PreADMET. 
The materials, we used the 4-(tert-butyl)-N-(methylcarbamothioyl)benzamide,  ethanol p.a, 
FeCl3.6H2O p.a, Bis-(4-(tert-butyl)-N-(methylcarbamothioyl) benzamide)-Iron (III) complex, 
Dimethyl sulfoxide (DMSO), and 2EUD.pdb. 
 
Synthesis of metal complex  
The 4-(tert-butyl)-N-(methyl carbomethyl)benzamide as much as 0.992 moles liquefied in 
30 mL ethanol (solution A) and 0.496 moles of metal FeCl3.6H2O in ethanol (solution B), then it 
(B) was dropped into solution A little by little. The drip process was under low heating and done 
gradually. For about 7 hours at 75oC we reflux it while stirring it using a magnetic stirrer. After 
that, we evaporate it slowly (Mardianingrum et al., 2019). 
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The purity test with hot stage microscopy 
The Bis-(4-(tert-butyl)-N-(methylcarbamothioyl) benzamide)-Iron (III) complex on the slide 
was set on a hot stage. Then the temperature is gradually increased at a constant speed, and the 
melting process is observed with a polarization microscope (Šimek et al., 2014). 
 
UV-Vis spectrophotometry 
DMSO with a concentration of 100 ppm and 200 ppm, is used to dematerialize standards and 
samples. Then used the electronic spectrum from a UV-Vis spectrophotometer to measure it in the 
200 nm - 800 nm area, and the absorbance was observed based on the maximum wavelength 
(Ruswanto et al., 2019). 
 
Infrared spectrophotometry 
The next process is to take 5 mg of KBr powder to be crushed on a mortal until homogeneous 
crushed. A cleaned pellet maker which has been dried with chloroform, ready to be used to make 
pellets transparently. The resulting pellets were then measured in the 4400-400 cm-1  wave area to 
be used as spectra (Ruswanto et al., 2018). 
 
Mass spectrophotometer (MS) 
MS settings were executed on capillary 3 kV, sampling cone 20, Extraxtion Cone 2, source 
temperature 120, Desolvation temperature 250, Flow Cone gas 50 L / hour, Flow Desolvation Gas 
800 L / hour, and sampling flow 20 micro L / min. Figure 4 presents the mass spectrum. The 
molecular ion peak at m / z 559.31, equal to the complex molecular weight, which was detected in 
the mass spectrum of Bis- (4- (tert-butyl) -N- (methylcarbamothioyl) benzamide) -Iron (III) 
(Mardianingrum et al., 2019). 
 
Molecular docking 
AutodockTools-1.5.6 software was used to create ligands with receptors. Then using 2EUD 
to retrieve ribonucleatide reductase enzyme data from the PDB website http://rcsb.org (Xu et al., 
2006). This was done to obtain the value of  root-mean-square-deviation  (RMSD), Gibbs free 
energy (ΔG)/ binding affinity for compounds/ ligands and complex compounds. After that, 
observing the interaction of receptors with ligands and receptors with complex compounds, and 
using Discovery Studio software version 16.1 to create its 2D visualization  (Pal et al., 2019). 
 
PREADMET and toxicity 
The process was continued by utilizing PreADMET, a web-based application on 
http://preadmet.bmdrc.org/. After the structure of the compound was converted into molfile *.mol 
(molfile) format, PreADMET will calculate the predicted absorption for Caco2 cells, HIA (Human 
Intestinal Absorption), plasma protein binding (PPB) and their toxicity parameters through the 
Ames test automatically. (Rozano et al., 2017; Yamashita et al., 2000; Yee, 1997; Zhao et al., 2001). 
 
RESULT AND DISCUSSION  
Synthesis of the Bis-(4-(tert-butyl)-N-(methylcarbamothioyl) benzamide)-Iron (III) Complex 
Ligands are electron pair donors. Each atom has a lone pair that coordinates covalently with 
the iron. The iron that was reacted to become a ligand will become complex, with the ratio of mole 
metal:ligand is 1:2. One of them must be significantly larger so that the equilibrium of the reaction 
changes to the right because FeCl3.6H2O can react absolutely with 4-(tert-butyl)-N- 
(methylcarbamothioyl)benzamide. The result of the reaction scheme is in Figure 1. 
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Figure 1. The reaction proposed of ligand and iron (III) 
The reflux process needed 7 hours at 75oC. For better results, the process must be longer. 
The stirring process used a magnetic stirrer. The process will cause the particles to collide with 
each other, thereby affecting the increase in the kinetic energy of the molecules. 
To obtain crystals complex, the reflux result was then slowly evaporated. It was reached 
85.85% in powder and brownish-yellow.  
 
The purity test results 
The melting point distance check was used to make sure that the compound produced was a 
new and not a starting material. The compound was assumed to be pure if the melting point 
difference reach about 2oC. Check on Table 1 for the result. 
 
Table 1. Melting point of the compounds 




The melting point diversion between the synthesis product and a starting material can 
illustrate that the new compound has been synthesized powerfully, and it was predicted as the 
complex. 
 
Characterization and Identification of Complex 
As the first structure, the synthesized compounds (MS) were then characterized and 
identified structurally using IR spectrophotometry, UV-Vis spectrophotometry, and mass 
spectrophotometry. That was done to set the maximum shift in wavelength to release the spectral 
profile of it, which it was then compared to the spectral profile of compound 4-(tert-butyl)-N-
(methylcarbamothioyl)benzamide and Bis-(4-(tert-butyl)-N-(methylcarbamothioyl) benzamide)-
Iron-benzamide (III). Then the results were obtained as in Table 2 which shows the value of the 
maximum wavelength (λ max) absorbance (A) of the compounds in the DMSO solvent and Figure 
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Figure 2. The overlay of the UV-Vis spectra of the starting material and the complex 
 
The hypochromic shift occurs due to a more polar solvent that is moving n→π* where the 
organic molecule has an unsaturated functional group so that the double bonds in the group provide 
the required  orbitals. The ground state in some of the transitioning particles becomes more polar 
than the excited state. (Santos et al., 2015). There is a shift in the maximum wavelength towards 
the smaller or hypochromic (blue shift) spectrum of Fe3+ (260.00 nm) from the FeCl3.6H2O solution 
to the Fe3+ spectrum from Bis-(4-(tert-butyl)-N-(methylcarbamothioyl)benzamide) Iron (III) 
solution. This indicates a complex formation. 
Table 3 shows the size of λmax shift, absorbance (A) and molar absorption (ε), and cleavage 
energy (10 Dq) of the Bis-(4-(tert-butyl)-N-(methylcarbamothioyl)benzamide) Iron (III) complex. 
 
Table 3. Electronic spectrum and value 10 Dq [13] 






A ε  
(L.mol-1. cm-1) 
FeCl3.6H2O 270 242.00 41322.314 3.602 4878.378 
4-(Tert-Butyl)-N-(Methylcarbamothioyl)Benzamide 250.36 281.00 35587.188 1.117 1329.365 
Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl)Benzamide)-Iron(III) 556.56 260.00 38461.538 0.805 2150.309 
 
The next test is infrared spectrophotometry which was carried out to obtain functional group 
information on the synthetic compounds produced. This complex showed that the C=O vibration 
absorption is located in 1627 cm-1, which the vibration frequency decreased due to the mesomeric 
effect. Based on the theory, the C=C vibration absorption is in 1680-1600 cm-1, while the C-N bond 
strain absorption is at 1326 cm-1. The absorption of metal vibrations with the O group of the ligand 
will also appear at the wave number 600-400 cm-1. Based on the theory, the metal vibration 
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absorption with an O group of the ligands will appear at a wavenumber of 600-400 cm-1. The Fe-O 
vibration absorption analysis result of the complex compound Bis-(4-(Tert-Butyl)-N- 
(Methylcarbamothioyl)Benzamide)-Iron (III) appeared in the 478.2 cm-1 and 588 cm-1, and The Fe-
N vibration absorption analysis result of the complex compound Bis-(4-(Tert-Butyl)-N- 
(Methylcarbamothioyl)Benzamide)-Iron (III) appeared in the 356.5 cm-1 (Rao and 
Venkataraghavan, 1962; Santos et al., 2015; Saratovskikh et al., 2013; Wang and Andrews, 2006). 
Table 4 shows the infrared data, and Figure 3 shows the infrared spectrum data. 
 
 
Figure 3. Infrared Spectrum for the ligand 4- (Tert-Butyl) -N- (Methylcarbamothioyl) 
Benzamide (blue); the Infrared Spectrum for the Bis- (4-(Tert-Butyl)-N-
(Methylcarbamothioyl) Benzamide) -Iron (III ) complex (Orange) 
 
Table 4. The comparison of infrared data for Bis- (4- (Tert-Butyl) -N- (Methylcarbamothioyl) 




























The next characterization was Mass Spectrophotometry (MS). It proved that the Bis-(4-(Tert-
Butyl)-N-(Methylcarbamothioyl) Benzamide) -Iron (III) complex was obtained in a pure condition. 
In Figure 3, we can see that the result of molecular ion peak has an m/z value of 559.31. 
Theoretically, the calculation of the complex molecular weight is 556.56. It indicates that the 
complex compounds from the one-step acylation synthesis are by the approximate structure in 
Figure 3. 
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Figure 3. Molecular mass spectrum analysis of Bis- (4- (Tert-Butyl) -N- 
(Methylcarbamothioyl) Benzamide) -Iron (III) Complex Compounds 
 
Based on the characterization in IR and MS spectrophotometry, the approximate structure of 
the Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl)Benzamide) -Iron (III) complex is shown in 
Figure 4. In this study, the complex's crystal structure has been described and it will not be discussed 
further here. However, the metal ion is coordinated to N, O and S-chelating anionic ligands for this 
complex and exhibits a distorted square planar geometry of coordination. (Do Couto Almeida et 
al., 2016).  
 
 
Figure 4. The proposed of the Bis-(4-(Tert-Butyl)-N (Methylcarbamothioyl) 
Benzamide)-Iron (III) structure complex 
 
From Figure 4 we will find the formation between 4-(Tert-Butyl) -N- (Methylcarbamothioyl) 
Benzamide with Fe (III) metal which occurs in O, S, and one N groups of NH2, from the lone 
electron pair derived from of these atoms, and used to bond with the metal Fe (III) to form the Bis-
(4-(Tert-Butyl)-N (Methylcarbamothioyl) Benzamide)-Iron (III). 
 
Complex molecular docking 
In the molecular docking process, the first step we must prepare the 4-(Tert-Butyl)-N- 
(Methylcarbamothioyl) Benzamide ligand and the receptors (2EUD.pdb) (Xu et al., 2006). 
Molecular docking aims to predict the conformation of bond and binding affinity. The Gibbs free 
energy (ΔG) value/ binding affinity will be pull out from the docking process. This process was 
carried out using AutodockTools-1.5.6 software between Bis- (4-(Tert-Butyl)-N-(Methylcar 
bamothioyl) Benzamide) -Iron (III) ligands with anticancer receptors. This process has several 
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stages, including ligand preparation, receptor preparation, validation of the docking method, 
docking of test ligands against the target receptor, analysis of docking results, PreADMET test. The 
recapitulation of docking results can be check in Table 5. 
 






Natural ligands 2EUD -8.23 32.21 μM 
4-(Tert-Butyl)-N-(Methylcarbamothioyl)Benzamide -6.47 18.03 μM 
Bis-(4-(Tert-Butyl)-N-
(Methylcarbamothioyl)Benzamide)-Iron(III) 
-8.52 568.55 nM 
 
The complex compound Bis- (4- (Tert-Butyl) -N- (Methylcarbamothioyl) Benzamide) -Iron 
(III) has a binding affinity of -8.52 kcal.mol and an inhibition constant of -8.52 kcal.mol 568.55 
nM. This is lower than the native ligand or 4- (Tert-Butyl) -N- (Methylcarbamothioyl) Benzamide. 
The differences were in the value of the binding affinity and the inhibition constant. Therefore, 
Table 5 concludes that the produced complex compounds are predicted to have the most stable 
interactions. 
Table 6 explains the interaction between the ligand 4-(Tert-Butyl)-N-(Methylcarbamothioyl) 
Benzamide with amino acid residues at the receptor and the Bis-(4-(Tert-Butyl)-N- 
(Methylcarbamothioyl) Benzamide) -Iron (III) complex with amino acid residues.  
 
Table 6. The interaction between ligands with amino acid residues 
Compounds Hydrophobic Bond Hydrogen Bond 
Native ligand ALA 245, GLY 247, LEU 
427, MET 606, PRO 607, L 
YS 292, PHE 206, PRO 203, 
TYR 155, ALA 201 
GLY 246, SER 217, 
CYS 218,THR 608, 
ALA 609, SER 610, 





ALA 296, GLY 247, PRO 
203, SER 217, ALA 201, 
ALA 245, LYS 292, PHE 
206, GLU 430 
ARG 293, 






ASN 291, SER 610, PRO 
203, ALA 201, THR 611, 
ALA 296, TYR 742, PHE 
403, THR 608, LEU 445, 
SER 217, ALA 609, PRO 
607, MET 606, GLY 290, 
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Figure 5. The 2D visualization of native ligand (a), the 2D visualization of 4-(Tert-Butyl) 
- (Methylcarbamothioyl) Benzamide (b), the 2Dvisuzlization of  Bis-(4- (Tert-
Butyl)-( Methylcarbamothioyl) Benzamide) -Iron (III) complex (c) 
 
Table 6 and Figure 5 explained that the amino acid residue that interacts the hydrogen bond 
with all compounds is SER 202, while the amino acids that have the most hydrophobic interactions 
are with complex compounds (about 18 amino acid residues: ASN 291, SER 610, PRO 203, ALA 
201, THR 611, ALA 296, TYR 742, PHE 403, THR 608, LEU 445, SER 217, ALA 609, PRO 607, 
MET 606, GLY 290, LYS 292, SER 154, TYR 741). Meanwhile, 3 amino acid residues interact 
hydrophobically with all compounds, namely PRO 203, ALA 20 and LYS 292. 
The Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl) Benzamide)-Iron (III) complex was 
tested for ADME (Absorption and Distribution) and toxicity using PreADMET server, which can 
be read at https://preadmet.bmdrc.kr/. The purpose of the ADME test is to shape the 
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93.865 25.6117 92.643 Mutagen 
Bis-(4-(Tert-Butyl)-N-
(Methylcarbamothioyl)Benzamide)-Iron(III) 
97.83.87 24.128 100 Mutagen 
Classification: HIA (%) 0-20 = not well absorbed. 20-70 = moderately absorbed. 70-100 = well absorbed; 
Caco-2 (nm/sec)<4 = low permeability. 4-70 = moderate permeability.> 70 = high 
permeability; PPB (%)> 90 = strongly bound. <90 = weakly bound. 
 
Plasma protein binding (PPB) value is more than 90%. It caused the Bis- (4- (Tert-Butyl) -
N- (Methylcarbamothioyl) benzamide) -Iron (III) complex and its comparison compounds have 
strong bonds with plasma proteins. It can be said to be lacking in distribution. In HIA, it is in the 
well-absorbed category, and based on Caco2 it has moderate permeability. All of these are 
presented in Table 7. 
Permeability coefficient as permeability to Caco2 single-layer cell culture, not only related 
to hydrogen bonding capacity and ionic charge, but also lipophilicity. Permeability is a function of 
various Physico-chemical parameters, namely permeability = f (lipophilicity, molecular size, 
hydrogen-bonding capacity, and charge). Descriptors have a positive correlation with% HIA. Those 
are the number of rotational bonds (Nrot), number of hydrogen bond donor groups (Hdon), number 
of hydrogen bond acceptor groups (Hacc), logarithm of octanol-water partition coefficient (Log P) 
and logarithm of solubility coefficient (Log S). Plasma protein binding (PPB) is a fraction of the 
available drug in free form for distribution to various tissues. Human plasma contains 70% protein, 
with albumin (HAS, human serum albumin), -1-glycoprotein acid (AGP, alpha-acyd 
glycoprotein), and lipoproteins as the main components. It is easier to bind with acidic or neutral 
drugs, whereas AGP and lipoproteins with essential medications. 
The toxicity parameter can be find from the mutagenic properties of the tested compound. 
Mutagens are compounds that can increase the rate of changes or mutations in genes so that they 
can trigger cancer development (Nursamsiar et al., 2016). The results of toxicity prediction using 
the PreADMET program showed that the Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl) 
Benzamide) -Iron (III) complex and its comparators had mutagenic properties. Although these 
compounds are mutagenic, they can still be used as drug candidates at the right dosages  (Yamashita 
et al., 2000; Yee, 1997; Zhao et al., 2001). 
 
CONCLUSION 
We concluded that the Bis-(4-(Tert-Butyl)-N-(Methylcarbamothioyl) Benzamide ) -Iron (III) 
complex could be synthesized from the reaction between the 4-(Tert-Butyl)-N-
(Methylcarbamothioyl) Benzamide with FeCl3.6H2O, and the complex yield was obtained by 
85.85%. 
We analyzed the molecular docking and concluded that the complex's interaction was better 
than the initial ligand, so the complex could be used as an anticancer candidate.  
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